Anticancer Activity of tin Oxide and Cerium-Doped Tin Oxide Nanoparticles Synthesized from Ipomoea Carnea Flower Extract

Background: The aim of the study is to investigate the anticancer potential of tin oxide (SnO2) and different concentrations (2%, 4%, 6%, and 8%) of cerium-doped tin oxide nanoparticles (Ce-SnO2 NPs) using Ipomoea carnea flower extract. The synthesized SnO2 and different concentrations (2%, 4%, 6%,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedical and Biotechnology Research Journal 2022-07, Vol.6 (3), p.337-340
Hauptverfasser: Prasanth, Manivannan, Muruganandam, Gurusamy, Ravichandran, Krishnasamy, Jeyaleela, Gnanasekar Dayana, Shanthaseelan, Krishnasamy, Priyadharshini, Baskaran
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: The aim of the study is to investigate the anticancer potential of tin oxide (SnO2) and different concentrations (2%, 4%, 6%, and 8%) of cerium-doped tin oxide nanoparticles (Ce-SnO2 NPs) using Ipomoea carnea flower extract. The synthesized SnO2 and different concentrations (2%, 4%, 6%, and 8%) of Ce-SnO2 NPs was tested using a colorimetric-based 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay against MCF-7 human breast cancer cell line cells. Methods: Collection and preparation of plant extract is preliminarily carried out followed by the synthesis of Undoped and Cerium doped Tin oxide nanoparticles is achieved by standard protocol along with that its anticancer activity also studied in this research. Results: The anticancer activity increased in direct proportion to the cerium-dopant concentration. Experimental results demonstrated that 8% Ce-SnO2 NPs exhibited a potential anticancer effect compared with SnO2 and other concentrations of Ce-SnO2 NPs. Conclusion: According to the current findings, large-scale manufacturing of Ce-SnO2 NPs might be recommended to have effective anticancer agents against breast cancer cell lines.
ISSN:2588-9834
2588-9842
DOI:10.4103/bbrj.bbrj_100_22